Skip to content
CancerIndex

Publication

PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition.

Authors not recorded

Cancer Cell2016PMID 27451907PMC4982440stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (5)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 5

Curated evidence

Evidence citing this paper (3)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
27451907
Run
ING-CIVIC-20260908-000001
Open at source
CuratedShowing 1–3 of 3 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
SGK1 Overexpression3
AlpelisibMalignant Breast NeoplasmPredictiveBSupports Resistance3accepted
EID1730

A group of 18 breast cancer patients were treated with PI3Kalpha inhibitor alpelisib (NVP-BYL719) plus an aromatase inhbitor (NCT01870505). 3 out of 3 patients expressing high tumor SGK1 mRNA had dise… (full text at CIViC)

PMID 27451907 · Castel et al., 2016 · Open in CIViC

civic
〃Malignant Breast NeoplasmPredictiveDSupports Resistance5accepted
EID1729

SGK1 mRNA expression was elevated in five breast cancer cell lines which were resistant to PI3Kalpha inhibitor alpelisib (NVP-BYL719) in comparison to five sensitive cell lines. Western blots showed c… (full text at CIViC)

PMID 27451907 · Castel et al., 2016 · Open in CIViC

civic
Alpelisib + SGK1-InhCombinationMalignant Breast NeoplasmPredictiveDSupports Sensitivity Response4accepted
EID1731

The alpelisib (PI3Kalpha inhibitor) resistant breast cancer cell line HCC1954 was treated with alpelsisb alone or in combination with the SGK1 kinase inhibitor SGK1-Inh. Addition of SGK1 reduced viabi… (full text at CIViC)

PMID 27451907 · Castel et al., 2016 · Open in CIViC

civic